

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 58017

Manuscript Type: EDITORIAL

Practice change in management of metastatic urothelial carcinoma after ASCO 2020

Pablo Gajate, Javier Torres-Jiménez, Carolina Bueno-Bravo, Felipe Couñago

Abstract

Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. During decades we have had few effective treatment options that impact in the prognosis of our patients. However, in the last years, several drugs have emerged as new treatment choices that are changing the therapy landscape of mUC. Immune checkpoint inhibitors (ICIs) and targeted agents are useful strategies of treatment that have been incorporated into our clinical practice. Nevertheless, cisplatin-based chemotherapy is still the

Match Overview

1	Internet 52 words crawled on 24-Aug-2020 www.esmo.org	2%
2	Internet 20 words crawled on 17-Dec-2019 www.frontiersin.org	1%
3	Crossref 19 words Matthew D Galsky, José Ángel Arranz Arija, Aristotelis Bamias, Ian D Davis et al. "Atezolizumab with or without chemoth	1%
4	Internet 19 words crawled on 30-Oct-2020 www.fda.gov	1%
5	Crossref 18 words Kiriakos S Hanna, Maren Campbell, Adam Kolling, Alex Husa, Sabrina Sturm, Dave Bello, Kimball Blake. "Updates in t...	1%
6	Crossref 16 words C Gridelli, C Gallo, M Di Maio, E Barletta et al. "A randomised clinical trial of two docetaxel regimens (weekly vs 3 weekl...	1%

国内版

国际版

Practice change in management of metastatic urothelial carcinoma



ALL

IMAGES

VIDEOS

278,000 Results

Any time ▾

[Management of Urothelial Bladder Cancer in Clinical ...](#)

<https://ascopubs.org/doi/10.1200/JOP.19.00215>

Aug 12, 2019 - Bladder **cancer** is the sixth most common malignancy in the United States, with 81,190 new patients projected to be diagnosed in 2018, 1 and the **urothelial carcinoma** histologic subtype composes 90% of bladder cancers. 2 Approximately 75% to 85% of patients present with disease confined to bladder mucosa or submucosa, which is classified as non-muscle-invasive bladder **cancer** ...

Cited by: 3

Author: Nataliya Mar, Farshid Dayyani

Publish Year: 2019

[Atezolizumab in patients with metastatic urothelial ...](#)

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.451

451. Background: Anti-tumor activity and manageable safety profile of atezolizumab (ATZ) has been demonstrated in the previous clinical trials in patients with locally advanced or **metastatic** platinum-resistant **urothelial carcinoma**. In this study, we reported the results of real-life data of **urothelial carcinoma** patients in Turkey who were treated with ATZ.

Author: Deniz Tural, Omer Fatih Olmez, Ahm...

Publish Year: 2020

[ASCO20 Virtual Scientific Program ... - Cancer.Net](#)

<https://www.cancer.net/blog/2020-05/asco20-virtual...> ▾

May 28, 2020 - **Urothelial carcinoma** is the most common type of bladder **cancer**. This study included 700 people with locally advanced or **metastatic urothelial carcinoma** that could not be treated with surgery. For all of these patients, the **cancer** had been stopped **after** receiving 4 to 6 cycles of platinum-based chemotherapy.

[ASCO 2020: Abstract Recommendations From Dr. Tom ...](#)

Search

Turn off



ALL

IMAGES

VIDEOS

577,000 Results

Any time ▾

[Management of Urothelial Bladder Cancer in Clinical ...](#)

<https://ascopubs.org/doi/10.1200/JOP.19.00215>

Aug 12, 2019 · Bladder cancer is the sixth most common malignancy in the United States, with 81,190 new patients projected to be diagnosed in 2018, 1 and the urothelial carcinoma histologic subtype composes 90% of bladder cancers. 2 Approximately 75% to 85% of patients present with disease confined to bladder mucosa or submucosa, which is classified as non-muscle-invasive bladder cancer ...

Cited by: 3

Author: Nataliya Mar, Farshid Dayyani

Publish Year: 2019

[ASCO 2020: Key abstracts and practice-changing findings](#)

<https://www.cardinalhealth.com/.../asco-2020.html> ▾

Business and practice management Business and practice management; ... ASCO 2020: Key abstracts and practice-changing findings . Browse Clinical insights Clinical insights ... the FDA recently approved avelumab for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, ...

[Phase I Study of Cabozantinib and Nivolumab Alone or With ...](#)

<https://ascopubs.org/doi/full/10.1200/JCO.20.01652>

Sep 11, 2020 · An estimated 362,860 new genitourinary (GU) tumors are expected to be diagnosed in the United States in 2020. 1 Treatment options for these tumors have changed in recent years. The US Food and Drug Administration recently approved seven new agents for metastatic urothelial carcinoma (mUC), including five immune checkpoint inhibitors (ICIs). 2-6 In addition, the development of antiangiogenic ...

Author: Andrea B. Apolo, Rosa Nadal, Daniel M. ... Publish Year: 2020

[Urothelial Carcinoma - ASCO 2020 GU Highlights ...](#)

<https://www.clinicaloptions.com/oncology/...> ▾

From ASCO 2020: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from CCO

[Immunotherapy trial in advanced bladder and other urinary ...](#)

<https://www.fredhutch.org/en/news/center-news/2020/...> ▾

'Practice-changing' data shows patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo September 18, 2020 · By Fred Hutch News Service staff Editor's note: This story was first published on June 3 shortly after the research was presented at the annual meeting of the American Society of Clinical Oncology.

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

577,000 Results

Any time ▾

[Updates in the management and future landscape of ...](https://journals.sagepub.com/doi/abs/10.1177/1078155220971026)

<https://journals.sagepub.com/doi/abs/10.1177/1078155220971026>

Urothelial carcinoma is the sixth most common **cancer** type in the United States. Although most patients present with early stage disease which is associated with improved outcomes, many will progres...

[ASCO 2020: Key abstracts and practice-changing findings](https://www.cardinalhealth.com/.../asco-2020.html)

<https://www.cardinalhealth.com/.../asco-2020.html> ▾

Business and **practice management** Business and **practice management**; ... **ASCO 2020**: Key abstracts and **practice**-changing findings . Browse Clinical insights Clinical insights ... the FDA recently approved avelumab for first-line maintenance treatment of locally advanced or **metastatic urothelial carcinoma**, ...

[Phase I Study of Cabozantinib and ... - ASCO Publications](https://ascopubs.org/doi/full/10.1200/JCO.20.01652)

<https://ascopubs.org/doi/full/10.1200/JCO.20.01652>

Sep 11, 2020 · An estimated 362,860 new genitourinary (GU) tumors are expected to be diagnosed in the United States in **2020**. 1 Treatment options for these tumors have changed in recent years. The US Food and Drug Administration recently approved seven new agents for **metastatic urothelial carcinoma** (mUC), including five immune checkpoint inhibitors (ICIs). 2-6 In addition, the development of antiangiogenic ...

Author: Andrea B. Apolo, Rosa Nadal, Daniel M. ... **Publish Year:** 2020

[Management of Urothelial Bladder Cancer in Clinical ...](https://ascopubs.org/doi/10.1200/JOP.19.00215)

<https://ascopubs.org/doi/10.1200/JOP.19.00215>

Aug 12, 2019 · Bladder **cancer** is the sixth most common malignancy in the United States, with 81,190 new patients projected to be diagnosed in 2018, 1 and the **urothelial carcinoma** histologic subtype composes 90% of bladder cancers. 2 Approximately 75% to 85% of patients present with disease confined to bladder mucosa or submucosa, which is classified as non-muscle-invasive bladder **cancer** ...

Cited by: 3

Author: Nataliya Mar, Farshid Dayyani

Publish Year: 2019

[Urothelial Carcinoma - ASCO 2020 GU Highlights ...](https://www.clinicaloptions.com/oncology/...)

<https://www.clinicaloptions.com/oncology/...> ▾

From **ASCO 2020**: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from ASCO